Advances in pharmacotherapy for secondary hyperparathyroidism

Bibliography

• Almaden Y, Canalejo A, Hernandez A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996;11:970-6
   PubMed Web of Science ®Google Scholar
• Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313-19
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-8
   PubMed Web of Science ®Google Scholar
• Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010;21:1125-35
   PubMed Web of Science ®Google Scholar
• Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Goto S, Fuiji H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010;77:232-8
   Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-408
   PubMed Web of Science ®Google Scholar
• Moe SM, Drüeke TB, Block GA, et al. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76:S1-S130
   Google Scholar
• Streja E, Lau WL, Goldstein L, et al. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Int 2013;3:462-8
   Google Scholar
• Lorenzo V, Martin M, Rufino M, et al. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 2001;37:1260-6
   Google Scholar
• National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-S201
   PubMedGoogle Scholar
• Caria S, Cupisti A, Sau G, et al. The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients. BMC Nephrol 2014;15:172
   Google Scholar
• Goto S, Nakai K, Kono K, et al. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease. Clin Exp Nephrol 2014;18:925-31
   Google Scholar
• Mircescu G, Garneata L, Hildegard-Stancu S, et al. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Renal Nutr 2007;3:179-88
   Google Scholar
• Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease. JAMA 2009;301:629-35
   PubMed Web of Science ®Google Scholar
• Smith AJ, Fougère MC, Abreo K, et al. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 1986;6:275-83
   PubMed Web of Science ®Google Scholar
• Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976;294:184-8
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-61
   PubMed Web of Science ®Google Scholar
• Emmett M, Sirmon MD, Kirkpatrick WG, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991;17:544-50
   PubMed Web of Science ®Google Scholar
• De Francisco ALM, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17
   PubMed Web of Science ®Google Scholar
• Covic A, Passlick-Deetjen J, Kroczak M, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013;28:2383-92
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ortiz ME, Canalejo A, Herencia C, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 2014;29:282-9
   PubMed Web of Science ®Google Scholar
• Neven E, De Schutter TM, Dams G, et al. A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats. PLoS One 2014;9:e107067
   Google Scholar
• Sakaguchi Y, Fuiji N, Shoji T, et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2013;85:174-81
   Google Scholar
• Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012;59:177-85
   PubMed Web of Science ®Google Scholar
• Lin HH, Liou HH, Wu MS, et al. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology (Carlton) 2014;19:672-8
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 2009;24:278-85
   PubMed Web of Science ®Google Scholar
• Joy MS, Finn WF; on behalf of the LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107
   PubMed Web of Science ®Google Scholar
• Hutchinson AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004;19:1902-6
   Google Scholar
• Zhai CJ, Yu XS, Sun QL, et al. Effect of lanthanum carbonate versus calciumbased phosphate binders in dialysis patients: a meta-analysis. Clin Nephrol 2014;82:372-8
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006;102:c61-71
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110:c15-23
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 2014;9:543-52
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Akiba T, Fukagawa M, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Renal Nutr 2014;24:261-7
   PubMed Web of Science ®Google Scholar
• Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014;7:191-201
   PubMedGoogle Scholar
• Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 2013;37:346-58
   PubMed Web of Science ®Google Scholar
• Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8:280-9
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014;86:638-47
   PubMed Web of Science ®Google Scholar
• Locatelli F, Spasovski G, Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2014;29:1061-73
   PubMed Web of Science ®Google Scholar
• Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005;20:1378-84
   PubMed Web of Science ®Google Scholar
• Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
   PubMed Web of Science ®Google Scholar
• The FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010;363:2287-300
   Google Scholar
• Rocco MV, Lockridge RSJr, Beck GJ, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 2011;80:1080-91
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Okazaki R, Takano K, et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990;323:421-2
   PubMed Web of Science ®Google Scholar
• Metzger M, Houillier P, Gauci C, et al. Relation between circulating levels or 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold. J Clin Endocrinol Metab 2013;98:2922-8
   Google Scholar
• Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis cronic renal failure. J Clin Endocrinol Metab 1988;67:929-36
   PubMed Web of Science ®Google Scholar
• Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa in chronic renal failure. N Engl J Med 1989;321:274-9
   PubMed Web of Science ®Google Scholar
• Dunlay R, Rodriguez M, Felsenfeld AJ, et al. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989;36:1093-8
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Caravaca F, Fernández E, et al. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 1999;56:306-17
   PubMedGoogle Scholar
• Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;5:S45-50
   Google Scholar
• Ross EA, Tian J, Abboud H, et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008;28:97-106
   PubMed Web of Science ®Google Scholar
• Han T, Rong G, Quan D, et al. Meta-Analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. BioMed Res Int 2013;2013:320560
   Google Scholar
• Trillini M, Cortinovis M, Ruggenenti P, et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 2014
   Google Scholar
• Jamaluddin EJ, Gafor AH, Yean LC, et al. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 2014;18:507-14
   Google Scholar
• Coyne DW, Goldberg S, Faber M, et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol 2014;9:1620-6
   PubMed Web of Science ®Google Scholar
• Al-Hilali N, Al-Humoud H, Al-Helal B, et al. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients. Ther Apher Dial 2008;12:137-42
   Google Scholar
• Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 2011;80:841-50
   PubMed Web of Science ®Google Scholar
• Wesseling-Perry K, Pereira RC, Sahney S, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor 23 in secondary hyperparathyroidism. Kidney Int 2011;79:112-19
   PubMed Web of Science ®Google Scholar
• Hayashi M, Tsuchiya Y, Itaya Y, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 2004;19:2067-73
   Google Scholar
• Akizawa T, Akiba T, Hirakata H, et al. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2015;19(3):225-34
   PubMed Web of Science ®Google Scholar
• Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011;6:50-62
   PubMed Web of Science ®Google Scholar
• Shroff R, Wan M, Gullet A, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012;7:216-23
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Lu JL, Malaskauskas SM, et al. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney dis 2012;59:58-66
   PubMed Web of Science ®Google Scholar
• Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012;96:672-9
   PubMed Web of Science ®Google Scholar
• Moe SM, Saifullah A, LaClair RE, et al. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010;5:299-306
   PubMed Web of Science ®Google Scholar
• Dusilová-Sulková S, Safránek R, Vávrová J, et al. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Int Urol Nephrol 2015;47:169-76
   PubMed Web of Science ®Google Scholar
• Taksande SR, Worcester EM. Calcium supplementation in chronic kidney disease. Expert Opin Drug Saf 2014;13:1175-85
   PubMed Web of Science ®Google Scholar
• Martins AM, Dias Rodrigues JC, de Oliveira Santin FG, et al. Food intake assessment of elderly patients on hemodialysis. J Ren Nutr 2015; pii:S1051-2276(14)00204-0
   Google Scholar
• Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 2012;81:1116-22
   PubMed Web of Science ®Google Scholar
• Armas LA, Zena M, Lund R, et al. Calcium absorption response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 2013;8:1003-8
   Google Scholar
• Gotch F. Calcium and phosphorus kinetics in hemodialysis therapy. Contrib Nephrol 2008;161:210-14
   Google Scholar
• Felsenfeld A, Rodríguez M, Burton L. New insights in regulation of calcium homeostasis. Curr Opin Nephrol Hypertens 2013;22:371-6
   PubMed Web of Science ®Google Scholar
• Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55:773-99
   PubMed Web of Science ®Google Scholar
• Molina-Vila P, Sánchez-Pérez P, Garrigós-Almerich E, et al. Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients. Hemodial Int 2008;12:73-9
   Google Scholar
• Jean G, Mayor B, Hurot JM, et al. Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone. Nephrol Dial Transplant 2013;28:176-82
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Valle C, Rodriguez M, Santamaria R, et al. Cinacalcet reduces the set point of the PTH-Calcium curve. J Am Soc Nephrol 2008;19:2430-6
   PubMed Web of Science ®Google Scholar
• Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 1998;53:223-7
   PubMed Web of Science ®Google Scholar
• Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-45
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, De Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186-93
   PubMed Web of Science ®Google Scholar
• Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013;10:e1001436
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Goodman WG, Liakopoulos V, et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review. Semin Dial 2015. [Epub ahead of print]
   Google Scholar
• Cohen JB, Gordon CE, Balk EM, et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation 2012;94:1041-8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE Study Results. Clin J Am Soc Nephrol 2008;3:1718-25
   PubMed Web of Science ®Google Scholar
• Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012;27:3270-8
   PubMed Web of Science ®Google Scholar
• Raggi P, Chertow GM, Urena-Torres P, et al. The ADVANCE study: a randomized, study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327-39
   PubMed Web of Science ®Google Scholar
• Ureña-Torres PA, Floege J, Hawley CM, et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 2013;28:146-52
   PubMed Web of Science ®Google Scholar
• The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
   PubMed Web of Science ®Google Scholar
• Locatelli F, Messa P, Bellasi A, et al. What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results. G Ital Nefrol 2013;30:5
   Google Scholar
• Koizumi M, Komaba H, Nakanishi S, et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012;27:784-90
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim H, Shin N, et al. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol 2013;14:112
   PubMed Web of Science ®Google Scholar
• Miller G, David J, Shatzen E, et al. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrol Dial Transplant 2012;27:2198-205
   Google Scholar
• Tatsumi R, Komaba H, Kanai G, et al. Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analysis. Nephron Clin Pract 2013;124:224-31
   Google Scholar
• Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 2013;346:229-40
   PubMed Web of Science ®Google Scholar
• Walter S, Baruch A, Alexander ST, et al. Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol 2014;15:81
   PubMed Web of Science ®Google Scholar
• Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide (AMG416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant 2014;29:385-92
   PubMed Web of Science ®Google Scholar
• Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int 2013;85:191-7
   Google Scholar
• Solbiati A, Giangrande A, De Pra L, et al. Percutaneous ethanol injection of parathyroid tumors under US guidance: treatment for secondary hyperparathyroidism. Radiology 1985;155:607-10
   PubMed Web of Science ®Google Scholar
• Onoda N, Fukagawa M, Tominaga Y, et al. New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients. NDT Plus 2008;1(Suppl 3):iii26-8
   Google Scholar
• Koiwa F, Kakuta T, Tanaka R, et al. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2006;22:522-8
   Google Scholar
• Douthat WG, Cardozo G, Garay G, et al. Use of percutaneous ethanol injection therapy for recurrent secondary hyperparathyroidism after subtotal nephrectomy. Int J Nephrol 2011;2011:246734
   Google Scholar
• Chen HH, Lin CJ, Wu CJ, et al. Chemical ablation of recurrent and persistent secondary hyperparathyroidism after subtotal parathyroidectomy. Ann Surg 2011;253:786-90
   PubMed Web of Science ®Google Scholar
• Chen HH, Lu KC, Lin CJ, et al. Role of the parathyroid gland vascularization index in predicting percutaneous ethanol injection efficacy in refractory uremic hyperparathyroidism. Nephron Clin Pract 2011;117:c120-6
   Google Scholar
• Saito A, Matsumoto Y, Oyama Y, et al. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism. Ther Apher Dial 2010;14:98-103
   Google Scholar
• Tanaka M, Itoh K, Matsushita K, et al. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract 2006;102:c1-7
   Google Scholar
• Takahashi H, Komaba H, Takahashi Y, et al. Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 2014;99:E652-8
   PubMed Web of Science ®Google Scholar
• Conzo G, Perna AF, Savica V, et al. Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetic era. BMC Surg 2013;13(Suppl 2):S4
   PubMedGoogle Scholar
• Akaberi S, Clyne N, Sterner G, et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991-2009. BMC Nephrol 2014;15:75
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE Trial. J Clin Endocrinol Metab 2013;98:4834-44
   PubMed Web of Science ®Google Scholar
• Eriguchi R, Umakoshi J, Tominaga Y, et al. Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl. NDT Plus 2008;4:218-20
   Google Scholar
• Florescu MC, Monirul Islam KM, Plumb TJ, et al. Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients. Int J Nephrol Renovasc Dis 2014;7:183-90
   PubMedGoogle Scholar